Gene-based maintenance therapy after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer, Genetic & congenital clinical trials.
This trial tests different maintenance therapies based on the specific gene mutations in your leukemia or MDS after a stem cell transplant. Your doctor will choose the right drug for your mutation type to help keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 14 and 75 years old
- You had your first stem cell transplant 30–60 days ago and the donor cells are now fully established
- Your leukemia or MDS has a specific gene mutation (like TP53, FLT3-ITD, KIT, or other high-risk changes) found by genetic testing
- Your cancer is in complete remission with no leftover cells detected by sensitive tests
- You have no active infection or graft-versus-host disease requiring treatment
- Your heart, liver, kidneys, and blood counts are within safe ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two drugs, selinexor and venetoclax, given after a stem cell transplant to keep high-risk leukemia or myelodysplastic syndrome from coming back. The goal is to see if this maintenance therapy is safe and effective for patients.
This trial tests two maintenance drugs (gilteritini and sorafenib) for people with FLT3-ITD positive AML after a stem cell transplant. It compares which drug better prevents relapse using a sensitive test for minimal residual disease (MRD).
This trial tests whether three targeted medicines (decitabine, venetoclax, and blinatumomab) can help prevent leukemia from coming back after a stem cell transplant. It is for people with B-cell ALL who have no detectable remaining leukemia cells and are at least 3 months past transplant.
This trial tests a pill called avapritinib to keep leukemia from coming back after a stem cell transplant. It is for people with AML that has a KIT mutation.
This study tracks how well a newer drug class (menin inhibitors) works to prevent acute leukemia from coming back after a stem cell transplant. You would be observed for safety and effectiveness if you're already taking one of these drugs.
This trial compares two drug combinations used before a stem cell transplant to see which is safer and more effective for people with acute myeloid leukemia (AML) that is in remission but still has minimal residual disease (MRD). The goal is to help prevent the leukemia from coming back after transplant.
Hear when a new MDS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.